• Publications
  • Influence
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
TLDR
FOLFIRi and FOLFIRI+Bev offered superior activity to their comparators and were comparably safe, and an infusional schedule of FU should be the preferred irinotecan-based regimen in first-line metastatic colorectal cancer. Expand
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
TLDR
Docetaxel was superior to paclitaxel in terms of OS and TTP and the overall response rate (ORR) was higher for docetaxe than for pac litaxel. Expand
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.
TLDR
It is possible to identify molecular targets in patients' tumors from nine different centers across the United States and in 27% of patients, the MP approach resulted in a longer PFS on an MP-suggested regimen than on the regimen on which the patient had just experienced progression. Expand
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
TLDR
At 5 years, TC was associated with a superior DFS and a different toxicity profile compared with AC, and both treatment groups were well balanced with respect to major prognostic factors. Expand
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
TLDR
The safety and activity of ibrutinib in elderly, previously untreated patients with symptomatic chronic lymphocytic leukaemia, or smallymphocytic lymphoma is encouraging, and merits further investigation in phase 3 trials. Expand
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
TLDR
Nanoliposomal irinotecan in combination with fluorouracil and folinic acid extends survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma who previously received gemcitabine-based therapy. Expand
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed
TLDR
OS did not improve with the Pemetrexed plus bevacizumab regimen compared with the PacCBev regimen, although PFS was significantly improved with PemCBev. Expand
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast
TLDR
A single subcutaneous injection of pegfilgrastim 100 microg/kg provided neutrophil support and a safety profile comparable to daily sub cutaneous injections of fil grastim during multiple chemotherapy cycles, consistent with a self-regulating neutrophils-mediated clearance mechanism. Expand
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology
TLDR
Consolidation docetaxel after PE/XRT results in increased toxicities but does not further improve survival compared with PE/ XRT alone in patients with stage III inoperable NSCLC. Expand
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
TLDR
Pembrolizumab did not significantly improve overall survival compared with paclitaxel as second-line therapy for advanced gastric or gastro-oesophageal junction cancer with PD-L1 CPS of 1 or higher and had a better safety profile than pac litaxel. Expand
...
1
2
3
4
5
...